News General

by Admin 2. April 2007 13:43









Plans to improve NHS uptake of medical devices

THE GOVERNMENT and the medical devices industry have published a report, Innovation for health: making a difference, which sets out plans for acceleration of the uptake of medical innovation across the NHS. It also gives a picture of what the medical device industry needs in order to grow and prosper.

Health Minister Lord Hunt said: “Medical innovation has a major role to play in helping the NHS improve quality of life for patients. This report outlines the achievements gained by Government and industry working in partnership and the further benefits to be realised from our continued co-operation.”

The report is the culmination of work by the Strategic Implementation Group, which was set up by the Healthcare Industries Task Force (HITF) to oversee the implementation of the key HITF outputs. The Strategic Implementation Group has agreed six recommendations: 


1. Working towards the adoption and implementation by the NHS of a procurement framework that will support the uptake of technologies and innovations leading to improved healthcare provision, patient safety and value for money.
2. A stocktake of existing support mechanisms and access to private finance for small and medium-sized medical device companies, and a review of what measures are needed to address any issues that are identified.
3. Development of a UK marketing strategy covering both inward investment and export opportunities for the main industry sub-sectors.
4. Measurement and analysis of the UK healthcare industry environment, focusing on success factors related to innovation, trade surplus and inward investment.
5. Government and industry to play an active role in the European Commission’s inquiry into the competitiveness of the European medical devices industry.
6. Creation of a new mechanism for engagement between Government and industry.


Sir Christopher O’Donnell, Chief Executive of Smith & Nephew, said: “Putting patients at the centre of all that we do is the key to aligning the interests of the Government, the NHS and industry. By focusing on mechanisms which accelerate the rate at which innovative treatments get from the laboratory to the front line of NHS care, we can create a virtuous circle.”

A new era for BIVDA

THE BRITISH In Vitro Diagnostics Association (BIVDA) has appointed a new President, Mr William Burns, and opened its new offices in central London. The new offices include a members’ resource centre. Their opening marks the 15th anniversary of BIVDA as the trade association for the UK IVD industry. Willie Burns has been Vice-President, International of Ortho-Clinical Diagnostics for the past six years. He has worked in the biotech and healthcare industries for the past 30 years, and for 25 of these has specialised in the IVD sector. Brian Fishwick has stepped down after three years as President of BIVDA.

Willie said: “During my career in the IVD industry, I have seen many changes as technologies have advanced, and my wish as President of BIVDA is to truly establish the value of diagnostics and to ensure these advances benefit patients in the healthcare continuum.”

The current Chairman of BIVDA, Jag Grewal commented: “BIVDA is delighted to welcome Willie Burns as President and to have such an experienced and dynamic individual to follow Brian Fishwick in this role. I look forward to working closely with Willie during the next few years. I would also like to thank Brian for his own invaluable contribution to the Association.”

BIVDA acts as the industry’s spokesman on issues related to IVD testing. It represents the UK in vitro diagnostics industry at the European Diagnostics Manufacturers Association (EDMA), which in turn represents the IVD industry in Europe. The membership of BIVDA currently represents over 95% of the UK diagnostics industry.

HSP founder moves on

HEALTH SECTOR PUBLISHING, the publisher of On Target, has bid farewell to Nick Merryfield, who founded the company. HSP thanks Nick for his hard work and innovation in the past 8 years, during which time he introduced Pharmaceutical Field, the UK’s first magazine for medical sales professionals, the Pf Awards, PSM, PharmaJobs and the benchmark Pf Company Survey. In 2006, Nick was General Manager of the team that acquired and developed On Target.

Frost & Sullivan recognise industry’s front runners

EXCEPTIONAL PERFORMERS in Europe’s healthcare industry were recognised at Frost & Sullivan’s Excellence in Healthcare Awards Banquet in London. Companies across the spectrum of the medical technologies sector were honoured at an event attended by over 50 industry leaders. 24 awards were presented in all, recognising such qualities as outstanding market leadership and enabling technologies, product and technology innovation, excellence in growth strategies and entrepreneurship.

• Eizo Nanao Corporation, GeneGo, Inc, InferMed Ltd, Mindray Medical International Limited, Speedel and Tandberg received awards for marketrelated strategies.
• Product-related awards were conferred on GenoID Ltd – The HPV Diagnostics Company, Medic4all, Medivance, Misys Healthcare Systems, NoemaLife, Peter Brehm GmbH Chirurgie Mechanik, Siemens Medical Solutions Diagnostics, ThermoFisher Scientific and Ziehm Imaging Group.
• Technology awards were given to AmVac AG, Capsule Technologie, Genaco Biomedical Products, Inc. and Luminex Corporation and Neuropharma S.A.

Debiotech SA received two awards, including the 2006 Entrepreneurial Company Award, while Barco Medical Imaging Division was given the Market Leadership Award. Mr. Guido Geerts, CEO of Rogan Delft BV, received the 2006 CEO of the Year Award for his leadership in the medical imaging market.

Stryker named as ‘UK Best 100’ company

THE SUNDAY TIMES has named medical technology company Stryker as the 44th ‘Best Mid-Size Company To Work For’ in the UK. The awards system draws on feedback from over 150,000 employees.

Louis Efron, Director of Human Resources at Stryker, said: “Stryker is about its people and that is why we are so proud of this listing. The company prides itself on a high service ethic, innovation and accountability – all elements which are embraced by every individual.”

Mr Tony Banks, Consultant Orthopaedic Surgeon with Bolton Hospitals NHS Trust, commented: “You can pick a Stryker person out in a crowd, there’s an energy about them you just don’t see very often. I believe it comes from a genuine desire to stand with me and focus on the best interests of my patients.”

The Sunday Times ‘Best Company to Work For’ survey is the only UK survey to rank companies on the basis of employee feedback. The participating companies are evaluated on leadership, rewards and recognition, work-life balance, opportunities for professional and personal growth, contribution to society and overall working environment.

Based in Newbury, Stryker UK markets, sells and distributes a broad-based range of products in orthopaedics and other medical specialities.

Industry-NHS partnership to invest in bright ideas

A GROUNDBREAKING PARTNERSHIP between Medipex, the NHS Regional Innovation Centre for Yorkshire and Humber, and private equity funders Exomedica will see £1 million made available to back innovative ideas within the NHS.

Under the terms of the three-year partnership, Medipex will use the money to back early-stage ideas arising from the NHS, covering the prototypes, staff time and other costs associated with developing and evaluating good ideas. Exomedica will have the opportunity to invest in selected projects; however, Medipex will be free to accept rival offers. Richard Clark, Chief Executive of Medipex, said: “Investment risks at such an early stage are very high, and the involvement of a private sector financial partner such as Exomedica is a massive vote of confidence in NHS Innovation Hubs and Medipex in particular.”

Exomedica has already committed to invest £250K in a joint venture with Medipex involving the creation of a start-up business to develop a cervical cancer diagnostic at Sheffield Teaching Hospitals NHS Trust. Several other commercial deals are under consideration.

Tags:

Medtech Features

Watchers at the gate

by Admin 1. April 2007 22:14
 

 

Watchers at the gate

Doris-Ann Williams, Director General of BIVDA, provides an overview of the commercial prospects for the in vitro diagnostics industry.

The past few years have been a difficult period for the healthcare industry. The procurement landscape has been focused on obtaining ‘best value for the NHS’ from suppliers, which has in reality meant lowest prices. There has been a distinct gap between industry’s perception of best value and that of the Commercial Directorate of the Department of Health.

This came to a head towards the end of 2006 on the industry side of the Strategic Implementation Group (a body representing both industry and Government to oversee the implementation of recommendations from the Healthcare Industries Task Force from November 2004). A final report, ‘Innovation for health: Making a difference’ (published on 6th March 2007) was delayed while Government sought to reassure industry that innovation would be included in metrics for future purchasing decisions.

At the same time, a number of initiatives impacted directly on different sectors of healthcare. The in vitro diagnostics (IVD) sector has, so far, been relatively unscathed, apart from the dramatic cut of 12% in reimbursement for blood glucose monitoring effective from October 2006.

Reluctant investment

However, the IVD sector has shown that for pathology services, it already offers the NHS exceptional value for money. The IVD sector in the UK has lower prices per test than most other Western countries, with a spend per capita in 2005 of 10.9 euros compared with France at 25.7 euros and Germany at 23.2 euros. The UK spends less on IVDs than even Spain and Greece (source: European Diagnostic Manufacturers Association). This is partly due to a lack of awareness of the value that diagnostics can add to healthcare, and partly due to industry reacting to a financial model for pathology in the NHS whereby laboratories have a fixed annual budget to operate under and are seen as an overhead by hospital administration.

The UK is notoriously slow to adopt new technology. This is frustrating for both commercial companies and laboratory professionals who wish to offer a comparable service to that available in other countries, utilising the latest techniques, equipment and markers for disease.

Making connections

Things are changing. Pressure on pricing will increase as Government struggles to control the rising costs of healthcare for an ageing population. However, it appears that adoption of new technology for IVDs will be assisted by a national tariff evolving either through Payment by Results or through the implementation of recommendations from Lord Carter of Coles’s review of pathology services (published last summer). This will help to address the effect of ‘silo’ budgeting.

Awareness of value for the IVD sector will be assisted as the sector becomes more integrated with in vivo diagnostics through Government policies such as the 18-week waiting time (which includes both in vivo and in vitro sectors) and, more significantly, through the acquisition of IVD companies by healthcare giants such as Siemens and GE Healthcare.

These acquisitions will raise the profile of the IVD sector and showcase the difference that diagnostics can make as a means of preventing disease and a gateway to more expensive testing, effectively saving money by ruling out the need for more invasive procedures.

Meanwhile, BIVDA will continue working in partnership with the laboratory professions to raise awareness of laboratory medicine with a new initiative, ‘Labs Are Vital’, to be launched at the FOCUS conference in Manchester at the end of April.


Doris-Ann Williams is Director General of the British In Vitro Diagnostics Association (BIVDA), the industry association representing manufacturers and distributors of IVD tests in the UK. For more information on BIVDA, contact Doris-Ann Williams directly or visit www.bivda.co.uk.

 

Tags:

Medtech Features

Editor's Comments

by Admin 1. April 2007 22:12

 

 

EDITOR’S COMMENTS

Balancing act

With Gordon Brown’s latest attempt to mimic the illusionist David Blaine still fresh in the mind, this month’s On Target takes a look at the important issue of budgets. Rather like Blaine’s endurance stunt in 2003, when he suspended himself in a Plexiglas case 30 feet above the South Bank on the river Thames for 44 days, healthcare budgeting is a question of balance. One step in the wrong direction, and you end up in deep waters.

Nowhere is attention to finance felt more heavily than in healthcare. The NHS is founded upon the principle that healthcare is free for all at the point of need. It attempts this within the constraints of a fixed budget, set by Government and funded by the taxpayer. Increasingly, this is becoming an impossible task.

In 1999, the New Labour government introduced NICE – an NHS regulator responsible for providing national guidance on the treatment of illness. It has been described as the organisation that decides whether or not you die for the want of medical treatment, on the basis of whether it is cost-effective to save your life. Its challenge is to find a balance between economics and human tragedy. In the context of a fixed-budget health plan that promises free healthcare for all, it’s a pretty tricky conundrum.

For the best part of a decade, good news about NICE has been fairly thin on the ground. But amid the current heat of a looming judicial enquiry and a plethora of protests from angry patient groups, On Target this month shows how NICE’s commitment to cost-containment is creating opportunities for the medical devices sector. In an exclusive interview with Professor Sir Michael Rawlins, we look at how the current focus on disinvestment may bring good news to medtech.
OT editor comments Elsewhere, we examine the challenges of the new NHS from a marketing perspective. ‘New customers, new challenges’ argues that the healthcare industry needs to go back to basics in order to update its marketing models for a customer base that is increasingly value-driven and concerned with balancing the books. To sell to the new budget-holders, we need to be able to demonstrate value not just at the clinical level, but at every level of customer service and cost-effective procurement.

Finally, to round off the issue, Mark Murphy offers a guide to the opportunities and pitfalls of the sales conference. His wry commentary on the means by which some industry professionals have used conferences to progress their careers, while others have wrought their own professional downfall, reminds us that whatever our spreadsheets and financial models tell us, it’s still the human touch that makes the difference.

In 2006, David Blaine broke a world record by remaining submerged beneath water for more than seven straight days. What kept him alive? A customised air regulator and an external, condom-style catheter. Testimony that, even in high-profile conjuring tricks to rival those of Gordon Brown’s recent budget, the medical device industry has an essential part to play.


Chris Ross
Editor

 

Tags:

Medtech Features

The lost weekend

by Admin 1. April 2007 22:06
 

 

As the sales conference season begins, Mark Murphy offers an essential weekend pack of things to remember in order to ensure that you take full advantage of the professional opportunities a sales conference offers – and resist some of the temptations!

Weekend sales conferences are an increasingly popular element of healthcare industry culture.

But what are they for? Are they primarily an opportunity for the sales force to ‘get acquainted’ in an informal environment – or do they serve real professional purposes? How can a healthcare sales professional make the most of a conference while avoiding the social pitfalls?

Morning after

Picture this scenario. Drifting slowly from a deep sleep into a semi-conscious state, he began to recall last night’s gala dinner. Having run through the events of the previous night – the professional faux pas, the excellent wines, the fuel for office gossip – he turned his attention to the day ahead. Day two of the conference: presenting to the whole company at 8.30am the new bonus and incentive scheme devised by their US parent company. This was his big day, and he intended to use this opportunity to his advantage by delivering some of his presentation in German. People would think he was great.

Having boosted his already over-inflated ego, he settled back onto the not-so-comfortable hotel pillows. Slowly opening his eyes, he became aware of the pounding in his head, a product of the excesses of the night before.

Hardly surprising: in six months of constant change under three Managing Directors, a guy had earned the right to let his hair down. He reached out for the glass of water that he vaguely recalled placing straegically on the bedside table, and as he did so finally opened his eyes. Great, he thought: it’s still dark, a few more hours of shut-eye and he would be as fresh as a daisy when he walked up onto the stage at 8.30 am. As the red LED clock on the TV in front of him came into focus, he read the numbers 10.37. Confused, he lay there trying to make sense of what he saw, but no amount of squinting would change the digits that confronted him.

A feeling of panic began to rise from his stomach. It couldn’t be: the dinner had finished at 9.30pm, and he was as sure as he could be that he’d partied for quite some time after. It also couldn’t be 10.37am as it was too dark; so he concluded that the clock on the TV must be set to New York time. He took a gulp of water and lay down. As he rolled over in an attempt to get comfortable, his eyes focused on the alarm clock on the table next to him, which displayed in bold: 10.38am. He struggled to find his watch and the light switch. Now it was 10.39am. He moved towards the window and pulled open the curtains, only to be almost knocked out by the brilliant sunshine that streamed through the windows – followed by the haunting realisation that his 8.30am presentation slot had long gone, along with his chance for recognition. How on earth was he going to get out of this?

Well, I could tell you but alas, as an ex- Director of Human Resources, I am bound by confidentiality to stop here. If only this was an isolated incident. During my 20 years in HR, I have had to deal with many individuals who, having behaved worse than this, have had their careers terminated as a result of inappropriate behaviour at conference. In various companies, it has been known for me to send HR Managers to conference in order to deal with behavioural issues as they arose. Our workload would always increase during the week following.

Don’t lose your foothold

As a conference delegate, you need to remember that even though the location may be different, it is still a work event and so you need to abide by your Company’s code of conduct. Please do not kid yourself that should you choose not to abide by the Company’s code, you can blame it on your employer since you were placed in a situation where alcohol was freely available. Oh, the number of times I have had to listen to this in post-conference disciplinary hearings. Well, I have to tell you that while this may be factually correct, you still have a duty of care to manage your consumption and act in a responsible way.

When attending conferences, think about how you can get the most out of them. If you want to progress your career, try to get yourself on the speaker list so that you have an opportunity to gain company-wide recognition. It’s a great way to get yourself noticed and raise your profile. Conferences can also provide a means of gaining knowledge about the company’s future plans and how you can contribute to them. However, if you are going to take it all in, you need to be psychologically as well as physically present!

For some, the life of a representative can be lonely. Courtesy of territory planning, they can be miles from any of their colleagues – so it’s a good chance for them to get to know each other and strengthen their network.

Think ahead

Sometimes conferences are used to deliver training on company-wide topics or product information. This can be a great way to reinforce what you know or to learn new facts and skills. Problems can arise at conferences because people have different expectations and requirements. Some may view it as a company party, with their mission being to have fun, while others may be leaving several dependants at home. For those who have had to move domestic mountains in order to attend, it is essential that the conference is worthwhile. Of course it is great if everyone can have an enjoyable time, but be mindful not to spoil it for yourself or others.

If you have the task of arranging a conference, take some time to consider the following:

• What is the main purpose of the event?
• Which of the following will it contain: whole-company presentations, team-building activities, professional training activities, talks given by company members, evening social gatherings?
• Does it make business sense to deliver these sessions at conference rather than at another time? • Does the timing take into account term-time and school holidays, so that working parents can attend?
• Is the location suitable for the purpose, and does it reflect the company’s image?

So, whether the aim of the conference is for staff to ‘get acquainted’, learn new skills or find out just how successful the company has been, make sure that you return full of enthusiasm for the future and not full of regret for the past!





Mark Murphy is a partner of The Portland Partnership, which specialises in offering professional skills programmes using accelerated learning principles. For further information, contact Mark at mark@portlandpartnership.com or Susan Glenn at susan@portlandpartnership.com or call 01494 670264.

 

Tags:

Medtech Features

Interview with a radiographer

by Admin 1. April 2007 22:03
 

The Other Side 9:

Interview with a radiographer

Kate Davis is a diagnostic radiographer working with a private healthcare company. On Target asked her about how the medical technologies industry supplies this crucial diagnostic sector.

1. Which imaging modalities do you work with, and what is your influence on purchasing decisions?

Although I have experience of working within all specialities of radiography, for the last 10 years my interest has been in Magnetic Resonance Imaging. In my capacity as a unit manager, I have some influence on purchasing decisions. This does depend somewhat on whether the equipment or drug is to be used company-wide or only in my unit. The company management team will make the appropriate decision regarding contract purchase of a contrast agent drug, for example. However, if I require a particular contrast for a specific patient, I am able to agree this locally following advice from the consultant radiologist and the clinician.

In the event of equipment being purchased by the host Trust from a charitable donation, I will often be tasked with sourcing the options and providing a breakdown of the literature for the teams involved.

For major purchases, such as a new MRI scanner, I am heavily involved in the evaluation and selection of the equipment. All the relevant models are graded against stringent specifications before a final decision is made regarding the choice of machine and manufacturer. In the case of MRI equipment, the evaluation panel consists not only of the relevant company employees but also of representatives from the host hospital for which we are providing the imaging service.

2. Do purchasing procedures for this kind of equipment in private healthcare differ significantly from those in the NHS?

In my experience they are fairly similar. Regardless of the sector in which you work, the purchasing goal of everyone involved is the same. Purchasers want to acquire the best quality equipment for the least amount of money, and to ensure that adequate follow-up and after-sales support are available. The same process of evaluation against cost is always undertaken and benchmarked by the purchasing team.

3. What are your priorities in terms of the products and customer service provided by the medical technologies industry?

How well does the industry meet your needs? For the product to be successful it must meet the specific requirements of the task, be cost-effective and be easily accessible. The product must have an excellent safety record and a streamlined order process.

In the case of a major equipment purchase (for example, an MRI scanner), customer service is vital, as are the level of warranty and the service packages available with the system. Access to efficient and helpful call centres with speedy dispatch of engineers is also graded in the evaluation process, as minimal downtime of medical equipment is essential to the provision of high-quality service to the end users.

Follow-up applications and access to the most recent software releases are also important areas for consideration.

Currently, the industry meets the needs of the company very well. There are a number of major scanner manufacturers in the marketplace, all with high-quality systems to offer. The choice of system we make from those available depends on the throughput and diversity of examinations required from the scanner. The diagnostics industry provides a choice of contrast agents, and the needs of the sterile services are catered for by the suppliers available.

4. What advice would you give to medical technology sales and marketing professionals in terms of how they work with companies like yours?

There is always a central purchasing team for the company. If the product you are trying to promote is something that would be utilised across all sites of the company, the first point of call should be the company head office. If the product is specific to a unit or patient following instruction from clinicians or radiologists, then usually the Unit Manager or the Superintendent Radiographer would be approached in the first instance. The provision of relevant literature is important – in particular, radiographers generally like to see a mixture of case studies to support the documentation. This always helps us to picture the kind of results that we are likely to achieve by using a new product.

5. What are you hoping to see in the future, in terms of new products and how these products are sold and supplied for healthcare?

As scanning sequences develop in the world of MRI, there will be opportunities for the development of new contrast agents. The technology of MRI scanning will develop over time, with improved image quality being produced in shorter scan times. This will undoubtedly lead to increased patient comfort and tolerance of the scanning process in all the patients referred to us.

The provision of relevant literature is important – in particular, radiographers generally like to see a mixture of case studies to support the documentation. This always helps us to picture the kind of results that we are likely to achieve by using a new product.

 

Tags:

Medtech Features

News People

by Admin 1. April 2007 22:01
 







Silchester Associates gain new team member

HEALTHCARE RECRUITMENT COMPANY Silchester Associates Ltd has recruited Lisa Nicholson to its team. Lisa will be heading up the new satellite office in Birmingham, and will be handling both UK and international projects.

Lisa initially trained as a nurse; she has 15 years’ experience of medical sales and medical recruitment within multiple clinical sectors. This complements the team’s already diverse coverage of clinical and technical healthcare specialities.

Silchester Associates has been based in Reading since 1999. The business expanded in 2004 with the introduction of the International and EMEA Division. Lisa said: “I am really delighted to be joining such an established and well-regarded agency, and I’m very much looking forward to working within the international sector as well as the UK market.”

To contact Lisa, call 07920 112182, e-mail lisa@silchesterassociates. co.uk or call the head office on 01189 635835. The Silchester Associates team

SSC appoints new Recruitment Manager

Richard Geddis SSC, a recruiter of healthcare sales and marketing professionals, has appointed Richard Geddis as Recruitment Manager for the UK. Richard will be responsible for managing the UK recruitment team, and for business development.

Richard joins from the Lifescan division of Johnson & Johnson, where he was Training & Development Manager following two years as Regional Business Manager. Prior to that, he was employed by SSC in a recruitment and management role. Richard said: “I’m delighted to be back at SSC. This is a much-changed company to the one I left four years ago. The acquisition by IHS means we can now offer a truly national service across the three offices and a wider service offering.”

Graham Hawthorn, Director at SSC & HIS, commented: “Getting Richard on board to lead the SSC team is a real coup for the company. He brings an unrivalled package of recruitment expertise and healthcare management experience.”

To contact Richard, call 020 7242 4266 or e-mail Richard@scientificstaff.com.

Oberoi recruits manager from PCT

OBEROI CONSULTING, a provider of dedicated IT solutions to healthcare, has appointed David Chan as Regional Account Manager for North London and the South-East. Over the last year, Oberoi’s service portfolio has expanded rapidly to match the changing NHS agenda. In addition to clinical audits, Oberoi now provides speaker meetings, practice accounting software training, business planning for practice takeovers and service redesign, training on the NHS agenda for the pharma industry and software extraction tools.

New Regional Account Managers are put through rigorous assessment centres to ensure that they are able to deliver Oberoi’s solutions. David Chan’s previous experience with Bexley Care Trust as an Improvement Foundation Lead in chronic disease management is one aspect of the skills and expertise he brings to his challenging new role with Oberoi. David Chan

UK Product Sales Manager appointed by Parafricta

Ann Hales Parafricta has appointed Ann Hales as UK Product Sales Manager to drive the launch of its range of low-friction garments and bedclothes. The Parafricta range is designed to help prevent the development of pressure ulcers in bed-ridden patients or patients with compromised skin.

Ann has worked in the woundcare industry for several years, including roles with Huntleigh-Healthcare (as a Product Specialist in its IPC Therapy team) and Johnson & Johnson (in its Advanced Woundcare Team).

“I am very excited to join Parafricta at this time,” Ann Hales said. “I look forward to driving the launch of these exciting products and establishing their place within the pressure sore relieving range of products available within both the UK and Europe.”

To contact Ann, call 07918 665161 or e-mail ann.hales@parafricta.com.

Tags:

Medtech Features

The Growing Trend: Patient Warming

by Admin 1. April 2007 21:59
 

The Growing Trend: Patient Warming

UK temperature management market hots up

The manufacturer of the world’s leading patient temperature management system, Bair Hugger® therapy, has renamed its UK sales & marketing subsidiary. On Target profiles Arizant UK Ltd.

The competitive field of patient temperature management systems in the UK is to undergo some cosmetic surgery of its own this month, with the name change of its leading player. Actamed Ltd., which has distributed the world’s major temperature management brands to the UK market for almost 15 years, has been renamed Arizant UK Ltd. The move cements Arizant UK’s standing as a specialist provider of temperature management systems, and is the final stage in an investment programme by global parent Arizant Inc., which invested in Actamed as a 25% shareholder six years ago and bought the company outright in 2004.

The Arizant name may currently appear unfamiliar to the UK market, but its flagship product has immediate recognition and widespread usage. Think of patient temperature management, and it’s highly likely that you’ll think of Bair Hugger therapy. By association, you’ll also be thinking of Arizant, the innovative US-based company that invented the brand, created the market and continues to develop it today.

The Bair Hugger system is the original forced-air warming product line and has helped Arizant lead the way in this growing sector. In fact, patient temperature management is now very much established as an important healthcare category and is clinically proven to improve patient outcomes for the areas in and around surgery.

Temperature specialists

The repositioning of Actamed as Arizant UK Ltd. is much more than a cosmetic name change. It crystallises the company’s transition from a distributor of surgical products that included, but was not exclusive to, temperature management products, to a dedicated provider of temperature management solutions.

Furthermore, it enables the company to build on the rich heritage of the Arizant brand, which is driven by a philosophy that continually strives for improvements in the quality of patient care through creativity and innovation.

Such innovation has seen Arizant develop a specialised product portfolio with true depth, encompassing patient warming systems, blood and fluid warming devices, temperature monitoring equipment and cooling systems. These are exciting times for Arizant UK and its customers. Later this year, the company plans to launch the Bair Paws patient adjustable warming system, which features a unique single-use warming gown that can be used throughout the perioperative process to provide comfort or clinical warming. The Bair Paws system is currently available in the US and Canada and is due to be introduced in the UK this summer. Likewise, a cooling product is also in late-stage development.

These products are all part of Arizant’s wider objective to eradicate the negative effects of hypothermia on more than 50 million surgical patients globally each year. Studies published in the Lancet and the New England Journal of Medicine demonstrate that patients who have been warmed may enjoy better health outcomes than those who haven’t.

Despite this, current data show that only about 30% of patients at risk of hypothermia, and the associated adverse outcomes such as an increased rate of wound infection, are actually being warmed. The challenge to improve the quality of life for the remaining 70% of patients provides Arizant with a real impetus to promote the value of patient temperature systems for health outcomes and to continue to innovate in its field. This, in turn, makes working for Arizant UK in such a dynamic market an attractive and rewarding proposition.

Arizant UK currently has 50 employees, around half of whom operate in sales and marketing. The company is justifiably proud of its reputation as an innovator and remains determined to enhance its position as an organisation that not only leads the market but, more crucially, shapes it.

Arizant UK achieves this through a commitment to speciality, rather than diversity. “We are specialists in the area of temperature management,” says Bob Buehler, Managing Director of Arizant UK Ltd. “Our portfolio is about depth. This gives us an opportunity to understand better how we can help our customers in our area of speciality.”

People helping patients

With this in mind, what kind of employee would find Arizant an ideal match? “An individual who is attracted to being a specialist would find a good home here,” says Buehler. “Of course, there are selling skills that every employer looks for in its sales force, and Arizant is no different.

But in addition, we look for individuals with a strong clinical background who can communicate as a specialist with our customers. This helps them convey why more people need to be warmed, and what this does for health outcomes. We want to help our customers understand that clinical story.”

Arizant UK’s key customers work primarily in anasthaesia, or as sisters and theatre managers in and around the surgical arena.

Arizant provides in-depth training for all employees, and has a group of clinical support specialists that not only develop the knowledge of its sales team but also focus on training external customers. This training is both product-based and clinical research-based.

The transition from Actamed to Arizant UK is a milestone for patient temperature management in the UK. Historically, Actamed has earned a strong reputation for high-quality customer service and products. This reputation is set to be further enhanced by the innovative, focused and forward-thinking culture of the Arizant brand.

“Arizant UK is the leader and specialist in patient temperature management,” says Bob Buehler. “The benefits of maintaining normothermia are significant and enable patients to have better outcomes, including fewer surgical site infections. We want to develop products that accelerate the impact of this important category of healthcare. So if you’re interested in developing and selling game-changing products, talk to Arizant UK.”

 

Tags:

Medtech Features

News General

by Admin 1. April 2007 21:56
 








Plans to improve NHS uptake of medical devices

THE GOVERNMENT and the medical devices industry have published a report, Innovation for health: making a difference, which sets out plans for acceleration of the uptake of medical innovation across the NHS. It also gives a picture of what the medical device industry needs in order to grow and prosper.

Health Minister Lord Hunt said: “Medical innovation has a major role to play in helping the NHS improve quality of life for patients. This report outlines the achievements gained by Government and industry working in partnership and the further benefits to be realised from our continued co-operation.”

The report is the culmination of work by the Strategic Implementation Group, which was set up by the Healthcare Industries Task Force (HITF) to oversee the implementation of the key HITF outputs. The Strategic Implementation Group has agreed six recommendations:


1. Working towards the adoption and implementation by the NHS of a procurement framework that will support the uptake of technologies and innovations leading to improved healthcare provision, patient safety and value for money.
2. A stocktake of existing support mechanisms and access to private finance for small and medium-sized medical device companies, and a review of what measures are needed to address any issues that are identified.
3. Development of a UK marketing strategy covering both inward investment and export opportunities for the main industry sub-sectors.
4. Measurement and analysis of the UK healthcare industry environment, focusing on success factors related to innovation, trade surplus and inward investment.
5. Government and industry to play an active role in the European Commission’s inquiry into the competitiveness of the European medical devices industry.
6. Creation of a new mechanism for engagement between Government and industry.


Sir Christopher O’Donnell, Chief Executive of Smith & Nephew, said: “Putting patients at the centre of all that we do is the key to aligning the interests of the Government, the NHS and industry. By focusing on mechanisms which accelerate the rate at which innovative treatments get from the laboratory to the front line of NHS care, we can create a virtuous circle.”

A new era for BIVDA

THE BRITISH In Vitro Diagnostics Association (BIVDA) has appointed a new President, Mr William Burns, and opened its new offices in central London. The new offices include a members’ resource centre. Their opening marks the 15th anniversary of BIVDA as the trade association for the UK IVD industry. Willie Burns has been Vice-President, International of Ortho-Clinical Diagnostics for the past six years. He has worked in the biotech and healthcare industries for the past 30 years, and for 25 of these has specialised in the IVD sector. Brian Fishwick has stepped down after three years as President of BIVDA.

Willie said: “During my career in the IVD industry, I have seen many changes as technologies have advanced, and my wish as President of BIVDA is to truly establish the value of diagnostics and to ensure these advances benefit patients in the healthcare continuum.”

The current Chairman of BIVDA, Jag Grewal commented: “BIVDA is delighted to welcome Willie Burns as President and to have such an experienced and dynamic individual to follow Brian Fishwick in this role. I look forward to working closely with Willie during the next few years. I would also like to thank Brian for his own invaluable contribution to the Association.”

BIVDA acts as the industry’s spokesman on issues related to IVD testing. It represents the UK in vitro diagnostics industry at the European Diagnostics Manufacturers Association (EDMA), which in turn represents the IVD industry in Europe. The membership of BIVDA currently represents over 95% of the UK diagnostics industry.

HSP founder moves on

HEALTH SECTOR PUBLISHING, the publisher of On Target, has bid farewell to Nick Merryfield, who founded the company. HSP thanks Nick for his hard work and innovation in the past 8 years, during which time he introduced Pharmaceutical Field, the UK’s first magazine for medical sales professionals, the Pf Awards, PSM, PharmaJobs and the benchmark Pf Company Survey. In 2006, Nick was General Manager of the team that acquired and developed On Target.

Frost & Sullivan recognise industry’s front runners

EXCEPTIONAL PERFORMERS in Europe’s healthcare industry were recognised at Frost & Sullivan’s Excellence in Healthcare Awards Banquet in London. Companies across the spectrum of the medical technologies sector were honoured at an event attended by over 50 industry leaders. 24 awards were presented in all, recognising such qualities as outstanding market leadership and enabling technologies, product and technology innovation, excellence in growth strategies and entrepreneurship.

• Eizo Nanao Corporation, GeneGo, Inc, InferMed Ltd, Mindray Medical International Limited, Speedel and Tandberg received awards for marketrelated strategies.
• Product-related awards were conferred on GenoID Ltd – The HPV Diagnostics Company, Medic4all, Medivance, Misys Healthcare Systems, NoemaLife, Peter Brehm GmbH Chirurgie Mechanik, Siemens Medical Solutions Diagnostics, ThermoFisher Scientific and Ziehm Imaging Group.
• Technology awards were given to AmVac AG, Capsule Technologie, Genaco Biomedical Products, Inc. and Luminex Corporation and Neuropharma S.A.

Debiotech SA received two awards, including the 2006 Entrepreneurial Company Award, while Barco Medical Imaging Division was given the Market Leadership Award. Mr. Guido Geerts, CEO of Rogan Delft BV, received the 2006 CEO of the Year Award for his leadership in the medical imaging market.

Stryker named as ‘UK Best 100’ company

THE SUNDAY TIMES has named medical technology company Stryker as the 44th ‘Best Mid-Size Company To Work For’ in the UK. The awards system draws on feedback from over 150,000 employees.

Louis Efron, Director of Human Resources at Stryker, said: “Stryker is about its people and that is why we are so proud of this listing. The company prides itself on a high service ethic, innovation and accountability – all elements which are embraced by every individual.”

Mr Tony Banks, Consultant Orthopaedic Surgeon with Bolton Hospitals NHS Trust, commented: “You can pick a Stryker person out in a crowd, there’s an energy about them you just don’t see very often. I believe it comes from a genuine desire to stand with me and focus on the best interests of my patients.”

The Sunday Times ‘Best Company to Work For’ survey is the only UK survey to rank companies on the basis of employee feedback. The participating companies are evaluated on leadership, rewards and recognition, work-life balance, opportunities for professional and personal growth, contribution to society and overall working environment.

Based in Newbury, Stryker UK markets, sells and distributes a broad-based range of products in orthopaedics and other medical specialities.

Industry-NHS partnership to invest in bright ideas

A GROUNDBREAKING PARTNERSHIP between Medipex, the NHS Regional Innovation Centre for Yorkshire and Humber, and private equity funders Exomedica will see £1 million made available to back innovative ideas within the NHS.

Under the terms of the three-year partnership, Medipex will use the money to back early-stage ideas arising from the NHS, covering the prototypes, staff time and other costs associated with developing and evaluating good ideas. Exomedica will have the opportunity to invest in selected projects; however, Medipex will be free to accept rival offers. Richard Clark, Chief Executive of Medipex, said: “Investment risks at such an early stage are very high, and the involvement of a private sector financial partner such as Exomedica is a massive vote of confidence in NHS Innovation Hubs and Medipex in particular.”

Exomedica has already committed to invest £250K in a joint venture with Medipex involving the creation of a start-up business to develop a cervical cancer diagnostic at Sheffield Teaching Hospitals NHS Trust. Several other commercial deals are under consideration.

Tags:

Medtech Features

New customers, new opportunities

by Admin 1. April 2007 21:55
 

















New customers,
new opportunities

Marketing strategies need to develop as the market for medical technologies evolves. Baba Awopetu and Akin Sawyerr look at how to access the new NHS budget holders.

AAs the dust settles over the changes in the NHS, we are left with some fundamental truths: both the NHS and the industry still have a unified objective of delivering better care to patients. How much has our working environment really changed? What changes do we need to make in order to ensure that we continue to thrive?

Decision makers

Our lifestyles and our ageing demography have combined to raise alarms about the unsustainable growing cost of healthcare, which is still largely funded by the Government. As a result, the NHS is reorganising and rethinking its operations. The outputs from this include increasing prevalence of buying groups, increasing powers for administrators and a greater emphasis on clinical outcomes to justify premium prices. Therefore many of us have drawn the prudent conclusion that our customers will have less influence on product choice in the future. The question is: how do we adapt to our new reality?

In today’s NHS, decision-making is a role for the group rather than the individual. While traditional customers such as nurses, doctors and hospital managers still remain key players, we now have to contend with broader decisionmaking groups that often contain both clinical and non-clinical customers. There has been a wider distribution of purchasing power across groups. One consequence of this is greater scrutiny on value delivery as the more financially astute members of the purchasing groups attempt to turn decision-making into a price-cutting exercise.

Inevitably, our propositions have to be articulated in clinical and financial terms. Our messages have to be tailored appropriately to the different members, even if the end objective remains the same. For decision-making groups concerned with cost containment, propositions that do not adequately address this priority will face a stiff barrier. Our expressions of customer-centricity will thus need to become broader.

The heat is on

Let’s consider why these changes seem to have arrived so suddenly. Is there perhaps another factor contributing to the new environment we are experiencing?

The theory of industry life cycles states that in its infancy, an industry has few players and these tend to have significant technological advantages. In our industry, patent-protected propositions with distinct advantages over their predecessors have been prevalent. Over a period of time, more players enter the field and their offerings move closer to the differentiated products of their predecessors. The gap narrows, and customers’ bargaining power increases as a result of choice between less differentiated product offerings.

At this stage in the life cycle, the baton is passed swiftly from R&D to marketing for differentiation. (In our industry, in fact, marketing feeds back into R&D to ensure that product design takes account of market segmentation.) R&D and good product development remain critical, although insufficient to ensure that the product will thrive in an increasingly crowded and differentiated market.

When this situation is combined with the environmental pressures on the NHS, the outcome is all the easier to understand. Like a frog being boiled slowly, we have failed to notice the subtle changes as they occurred – and while we were busy preparing for the future, we didn’t notice it had arrived! How can we succeed in this new and rugged landscape?

Segmentation is the key

Fortunately we have seen this in other industries, and we can learn from the way they have coped with life cycle impacts coupled with changes in customer dynamics. First and foremost, innovation has to move beyond the R&D team to sales and marketing operations.

As the chairman of Tesco famously said, “Paranoia is the secret of our success.” The healthcare industry cannot afford to be complacent: constant adaptation is essential.

We need a marketing culture that evolves continually to mirror a rapidly changing landscape. Return on investment, sales and marketing effectiveness should be permanent factors in our thinking. We need to adopt the active marketing approach of our FMCG counterparts – that is, to think customers first, profit second. Otherwise we will not connect with the market at all.

The concept of market segmentation is not always appropriately deployed in our industry. Segmentation means the division of customers into groups with similar needs – presumably so that we can meet these needs better. However, upon reviewing most of the approaches to segmentation within the industry, we see a tendency to segment for improved profit rather than for improved service delivery.

Often we look for the high-category groups that use a lot of our particular product type, so we can target them with our sales force. This approach may be simple, but the long-term result is inevitably suboptimal. We need to rethink our perspective on our customers and segment them in a meaningful way that allows us to meet their needs.

The changes in the healthcare environment make it even more critical that we foster a genuinely customer-focused culture: this is the only route to sustainable growth. Some of the new market segments are customers who are keen to cut costs – and to be fair, this is often prudent. This segment is not exclusive to administrators, nor are all administrators in this segment. Nonetheless, clarity on how our sales proposition helps them to achieve their aim is vital.

We need to get better at articulating the benefits of our offering beyond the clinical benefits – for example, more accurate diagnosis or faster treatment procedures save time and money by getting patients out of hospital faster.

Adding value

The new NHS can be summed up in a sentence: “Show me the value.” Rather than getting too engrossed with the new barriers in the market, what we really need is a focus on the end users. Our capacity to demonstrate that our services improve the lives of patients is critical to our future success.

In an environment with so many me-too propositions, only organisations that are able to differentiate their offering will survive the drive to cut costs. We said ‘propositions’ because in many scenarios, there is no denying the similarities between core products.

However, we can package services and support systems to further differentiate ourselves. Training, support, integration and patient education are some of the areas that our leading lights are using to demonstrate superior value.

In today’s NHS, there has been a wider distribution of purchasing power across groups. One consequence of this is greater scrutiny on value delivery as the more financially astute members of the purchasing groups attempt to turn decision-making into a price-cutting exercise.

The days of depending on technological advancement alone to help us demonstrate value are over. For example, branding (though still essential) needs to include more than the core product: we need to ensure that all our touch points reinforce our brand proposition. The winners in our industry will be those who can adapt quickly while holding onto classic marketing philosophy.

Our emphasis on customers needs to be broadened and updated. Despite the tougher environment, the industry can continue to be successful. Adaptations to our service delivery and communications will ensure success in meeting needs and generating profits.


Baba Awopetu is Senior Lecturer at The Marketer’s Forum and a freelance healthcare writer. He can be contacted at btawopetu@yahoo.co.uk. Akin Sawyerr can be contacted at sawyerrs@yahoo.co.uk.

 

Tags:

Medtech Features

MISSING - Madeline McCann age 4

by Admin 1. April 2007 21:53

 

 

MISSING - Madeline McCann age 4

Madeleine’s uncle is medical rep

The sad disappearance of Madeleine McCann from a Portugese holiday resort has undoubtedly touched the hearts of the national and international communities. But the disturbing story also has a connection with the medical representative community. Madeleine’s uncle, 48-year old John McCann, is a medical representative for AstraZeneca. AZ has granted John indefinite leave as he plays a central role in the international campaign to find Madeleine. Pf wishes to take this opportunity to extend its thoughts and sympathies to the McCann family, and, as does the rest of its loyal readership, prays for the safe return of Madeleine. For further details of the McCann’s campaign, please visit www.findmadeleine.com .

 

Tags:

Medtech Features

TextBox

Tag cloud

Calendar

<<  May 2013  >>
MoTuWeThFrSaSu
293012345
6789101112
13141516171819
20212223242526
272829303112
3456789

View posts in large calendar